Hidenori Matsuo

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Koji Abe, Masashi Aoki, Shoji Tsuji et al. · The Lancet Neurology · 2017 · 900 citations

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurological Disorder +6

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Ankle-Brachial Blood Pressure Index Predicts All-Cause and Cardiovascular Mortality in Hemodialysis Patients

Kumeo Ono, Akiyasu Tsuchida, Hironobu Kawai et al. · Journal of the American Society of Nephrology · 2003 · 226 citations

Hypertension, High Abpi, Cardiometabolic Risk +18

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · The Lancet Neurology · 2019 · 216 citations · Full text

Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE)

Tomohiko Kayashima, Hidenori Matsuo, Akira Satoh et al. · Journal of Human Genetics · 2002 · 114 citations · Full text

Mendelian Disorder, Genetic Disorder, Genetics +8